एवानाफिल और रियोसिगुआट का इंटरैक्शन

• Administration with guanylate cyclase (GC) stimulators such as riociguat and vericiguat ( 4.3 )

Concomitant Guanylate Cyclase (GC) Stimulators Do not use avanafil tablets in patients who are using a GC stimulator, such as riociguat or vericiguat.

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated.

When vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased.

When vasodilators are taken in combination, blood pressure-lowering effects of each individual compound may be increased.

Phosphodiesterase Inhibitors Concomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )].

PDE Inhibitors: Co-administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or theophylline), is contraindicated because of hypotension.

Clinical experience with co-administration of Adempas and other phosphodiesterase inhibitors (for example, milrinone, cilostazole, roflumilast) is limited.